Repurposing is a priority for the EU.1 Albeit of risk reduction and shorter development timelines, existing market mechanisms do not favor drug repurposing.
We believe that we also have cracked this code with four layers of market protection - in addition to having a drug that finally has real transformative prospects of relieving excruciating pain and being safe.
Can we convince the EIC in January?
1Front Med; Repurposing of Medicines in the EU: Launch of a Pilot Framework. Repurposing of Medicines in the EU: Launch of a Pilot Framework
